Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ladiratuzumab vedotin
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody targeting the zinc transporter protein LIV-1 (solute carrier family 39 member 6, SLC39A6), which is highly expressed in several solid tumors including breast cancer. The antibody is conjugated to a cytotoxic payload—monomethyl auristatin E (MMAE)—via a cleavable linker. Upon binding to LIV-1 on tumor cells, the ADC is internalized and releases MMAE inside the cell, leading to microtubule disruption, cell cycle arrest at G2/M phase, and apoptosis. Ladiratuzumab vedotin has shown activity as monotherapy and in combination with pembrolizumab in early-phase clinical trials for metastatic triple-negative breast cancer (TNBC) and other solid tumors expressing LIV-1[1][3][4][6][9].
- Brand names
- SGN-LIV1ASGN-LIV-1ASGN-LIV 1A
- Other names
- ladiratuzumab vedotinLV
02
Targets
SLC39A6 (Solute carrier family 39 member 6)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ladiratuzumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ladiratuzumab vedotin.